Sohee Oh

Sohee Oh

Auto-generated profile, based on publicly available information

Sohee Oh

Medical Research Collaborating Center, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Ki-Tae HwangKi-Tae Hwang
Ki-Tae Hwang
JKJongjin Kim
Jongjin Kim
JJJiwoong Jung
Jiwoong Jung
JCJi Hyun Chang
Ji Hyun Chang
YCYoung Jun Chai
Young Jun Chai
KHKyu Ri Hwang
Kyu Ri Hwang
Purpose: To determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer. Experimental Design: Data of 321,958 patients from Surveillance, Epidemiology, and End Results (SEER) database were analyzed. Breast cancer subtypes were classified into four categories according to the status of hormone receptor (HRc) and HER2: HRc(+)/HER2(−), HRc(+)/HER2(+), HRc(−)/HER2(+), and HRc(−)/HER2(−). Results: Proportions of HRc(+)/HER2(−), HRc(+)/HER2(+), HRc(−)/HER2(+), HRc(−)/HER2(−), and unknown subtype were 70.3%, 9.4%, 3.9%, 10.4%, and 6.0%, respectively. HRc(+)/HER2(−) showed the highest 5-year breast cancer–specific survival (BCSS) rate (95.5%), followed by HRc(+)/HER2(+) (94.1%), HRc(−)/HER2(+) (89.3%), and HRc(−)/HER2(−) (83.1%). HRc(+)/HER2(−) and HRc(+)/HER2(+) showed higher 5-year overall survival (OS) rates (88.4% and 88.2%, respectively) than HRc(−)/HER2(+) and HRc(−)/HER2(−) (83.9% and 76.5%, respectively). HRc(−)/HER2(−) showed the worst BCSS irrespective of race, age, or stage. Although proportions of HRc(−)/HER2(−) in the subgroup with negative event regarding BCSS and OS were 10.4% and 10.2%, respectively, they were 34.2% and 22.7%, respectively, in the subgroup with positive event. Subtype was a significant factor in both univariable and multivariable analyses regarding both BCSS and OS (all P < 0.001). Conclusions: Breast cancer subtype was a significant independent prognostic factor regarding both BCSS and OS in multivariable analyses. HRc(+) subtypes showed better prognosis compared with HRc(−) subtypes regarding both BCSS and OS. HRc(−)/HER2(+) showed better prognosis than HRc(−)/HER2(−) but worse prognosis than HRc(+) subtypes regarding both BCSS and OS. The triple-negative subtype showed the worst BCSS compared with the other subtypes irrespective of race, age, or stage.

19 March 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKSu Hwan Kim
Su Hwan Kim
JJJi Bong Jeong
Ji Bong Jeong
JKJinwoo Kang
Jinwoo Kang
DADong-Won Ahn
Dong-Won Ahn
JKJi Won Kim
Ji Won Kim
Doohee LeeDoohee Lee
Doohee Lee
Aims: Metabolic syndrome (MetS) increases the risk of diabetes mellitus (DM), cardiovascular disease (CVD), cancer, and mortality. Sarcopenia has been reported as a risk factor for MetS, non-alcoholic fatty liver disease, and CVD. To date, the association between sarcopenia and MetS has been investigated. However, there have been few studies on the dose-response relationship between sarcopenia and MetS. We investigated the association between sarcopenia and the prevalence of MetS. We also aimed to analyze the dose-response relationship between skeletal muscle mass and the prevalence of MetS. Methods: We enrolled 13,620 participants from October 2014 to December 2019. Skeletal muscle mass was measured using bioelectrical impedance analysis (BIA). Appendicular skeletal muscle mass (ASM) was divided by body weight (kg) and was expressed as a percentage (ASM x 100/Weight, ASM%). The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. Linear regression and logistic regression analyses were used to compare the clinical parameters according to ASM%, adjusted for age, sex, obesity, hypertension (HT), DM, dyslipidemia (DL), smoking, alcohol intake, and C-reactive protein (CRP). Multiple logistic regression analysis was performed to determine the risk of MetS in each group. Results: A dose-response relationship was identified between ASM% and MetS. Sarcopenia was associated with an increased prevalence of MetS. After adjustment for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, sarcopenia remained significantly associated with MetS. For each 1 quartile increment in ASM%, the risk of MetS decreased by 56% (P< 0.001). After adjusting for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, the risk of MetS decreased by 25% per 1Q increment in ASM% (P < 0.001). Conclusions: Sarcopenia by BIA is independently associated with the risk of MetS and has a dose-response relationship.

13 October 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
CJChris Hyunchul Jo
Chris Hyunchul Jo
SLSeung Yeon Lee
Seung Yeon Lee
KYKang Sup Yoon
Kang Sup Yoon
SOSohee Oh
Sohee Oh
SSSue Shin
Sue Shin
Background: The use of platelet-rich plasma (PRP) for the treatment of rotator cuff disease is still controversial. The purpose of the present study was to investigate the safety and efficacy of a fully characterized allogeneic pure PRP injection into the subacromial space of patients with rotator cuff disease in comparison with corticosteroid injection. Methods: A 2-group, parallel, assessor-blinded, randomized controlled trial was conducted. A total of 60 patients with clinically and structurally diagnosed rotator cuff disease were randomly assigned to receive a subacromial injection of either 4 mL of allogeneic pure PRP or a 4-mL mixture of 1 mL of 40-mg/mL triamcinolone acetonide and 3 mL of 2% lidocaine under ultrasonographic guidance. The primary outcomes were safety and the Constant score at 1 month. The secondary outcomes were pain, range of motion, muscle strength, functional scores, and overall satisfaction and function. Results: There were no treatment-related adverse events. The Constant score at 1 month did not significantly differ between the PRP and corticosteroid groups. At 6 months, the DASH (Disabilities of the Arm, Shoulder and Hand) score, overall function, and external rotation were significantly better in the PRP group than in the corticosteroid group, and the other clinical outcomes did not show significant differences. All pain measurements, the strength of the supraspinatus and infraspinatus, and 5 functional scores also improved slowly and steadily after injection, becoming significantly better at 6 months compared with those before the injection, whereas those in the corticosteroid group responded promptly but did not further improve. Conclusions: Allogeneic PRP injections for the treatment of rotator cuff disease are safe but are not definitely superior to corticosteroid injections with respect to pain relief and functional improvement during 6 months. The DASH score, overall function, and external rotation were significantly better in the PRP group than in the steroid group at 6 months. Generally, PRP slowly but steadily reduced pain and improved function of the shoulder until 6 months, whereas corticosteroid did not. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

3 February 2015 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
Ju Young KimJu Young Kim
Ju Young Kim
SOSohee Oh
Sohee Oh
SSSteven Steinhubl
Steven Steinhubl
SKSohye KIM
Sohye KIM
Woo Kyung BaeWoo Kyung Bae
Woo Kyung Bae
MKMi Jin Kim
Mi Jin Kim
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJin A Lee
Jin A Lee
MKMyo-Jing Kim
Myo-Jing Kim
SOSohee Oh
Sohee Oh
BCByung Min Choi
Byung Min Choi
Lee JA, et al. J Korean Med Sci. 2015 Oct;30(Suppl 1):S59-S66. https://doi.org/10.3346/jkms.2015.30.S1.S59

1 January 2019 in Journal of Breast Cancer
Verified
Journal Article
Open access
Ki-Tae HwangKi-Tae Hwang
Ki-Tae Hwang
BKByoung Hyuck Kim
Byoung Hyuck Kim
SOSohee Oh
Sohee Oh
SPSo-Yeon Park
So-Yeon Park
JJJiwoong Jung
Jiwoong Jung
WKWoo-Young Kim
Woo-Young Kim
Hwang KT, et al. J Breast Cancer. 2019 Jul;22:e55. https://doi.org/10.4048/jbc.2019.22.e55